Intabio, a Newark, Calif.-based developer of instrumentation systems for biotherapeutic precision analysis and quality assessment throughout bioproduction, raised $18m in Series B funding.
The round was led by Northpond Ventures, with participation from Genoa Ventures and Vertical Venture Partners.
The company intends to use the funds to build its commercial team and prepare for launch of the platform.
Led by CEO and co-founder, Lena Wu, Ph.D., Intabio is developing analytical solutions to facilitate biotherapeutic development and manufacturing with products that provide early product quality characterization and efficiency gains across all stages of biopharmaceutical development and manufacturing. The first product, the Blaze system, is a microchip-based instrument system that will provide rapid detection and identification of subtle protein modifications – modifications that can undermine the stability and efficacy of biotherapeutic drugs such as monoclonal antibodies and recombinant proteins.